Open access · CC-BY
via OpenAlex
Targeting Myotonic Dystrophy Type 1 with Metformin
Mikel García-Puga, Ander Saenz‐Antoñanzas, Ander Matheu, Adolfo López de Munaín
International Journal of Molecular Sciences · 2022 · ▲ 26 citations
Abstract
Myotonic dystrophy type 1 (DM1) is a multisystemic disorder of genetic origin. Progressive muscular weakness, atrophy and myotonia are its most prominent neuromuscular features, while additional clinical manifestations in multiple organs are also common. Overall, DM1 features resemble accelerated aging. There is currently no cure or specific treatment for myotonic dystrophy patients. However, in recent years a great effort has been made to identify potential new therapeutic strategies for DM1 patients. Metformin is a biguanide antidiabetic drug, with potential to delay aging at cellular and organismal levels. In DM1, different studies revealed that metformin rescues multiple phenotypes of the disease. This review provides an overview of recent findings describing metformin as a novel therapy to combat DM1 and their link with aging.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/ijms23052901
- Canonical
- link ↗
- Fetched
- 2026-06-14 MST
Cite this
APA
García-Puga, M., Saenz‐Antoñanzas, A., Matheu, A., & Munaín, A.L.D. (2022). Targeting Myotonic Dystrophy Type 1 with Metformin. <em>International Journal of Molecular Sciences</em>. https://doi.org/10.3390/ijms23052901
Vancouver
García-Puga M, Saenz‐Antoñanzas A, Matheu A, Munaín ALD. Targeting Myotonic Dystrophy Type 1 with Metformin. International Journal of Molecular Sciences. 2022. doi:10.3390/ijms23052901.
BibTeX
@article{mikel2022Target,
title = {Targeting Myotonic Dystrophy Type 1 with Metformin},
author = {Mikel García-Puga and Ander Saenz‐Antoñanzas and Ander Matheu and Adolfo López de Munaín},
journal = {International Journal of Molecular Sciences},
year = {2022},
doi = {10.3390/ijms23052901},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging 2020
Preprint · CC-BY
Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin
Basic & Clinical Pharmacology & Toxicology 2009
Open access · OA
Role of Marginal Vitamin C Deficiency in Atherogenesis: In Vivo Models and Clinical Studies
International Journal of Molecular Sciences 2021
Open access · CC-BY
Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges
ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) 2020
Preprint · OA
Metformin's Potential as a Form of Anti-Aging Therapy
Cells 2022
Open access · CC-BY
Metformin Prevents or Delays the Development and Progression of Osteoarthritis: New Insight and Mechanism of Action
Cells 2025
Open access · CC-BY